Expanding Clinical Research Beyond Borders:<br />	The Importance of Latin America<br />	Dr. Marlene Llopiz<br />Venn Life ...
Growing markets<br />Introduce Latin America (LATAM)<br />Describe what Latin America has to offer<br />What is available ...
Latin America (LA)<br />Drug Information Association<br />www.diahome.org<br />3<br />Regions:<br /><ul><li>Mexico
Central America
Caribbean
South America</li></ul>Clinicalresearchin:<br /><ul><li>Mexico
Argentina
Guatemala
Costa Rica
Panama
Colombia
Venezuela
Peru
Chile
Brazil</li></li></ul><li>Growing Markets Playing an Increasingly Important Role<br />Drug Information Association<br />www...
In recent years, several regions around the world have provided new frontiers for conducting phase I-IV clinical trials. <...
As a vastly populated and varied region, LA provides:<br /><ul><li>large drug naïve patient populations with common and sp...
rapid compliant patient recruitment,
motivated and experienced investigators,
USA and EC-equivalent medical standards, as well as
highly experienced monitoring and project management teams thoroughly trained on GCP and ICH guidelines. </li></ul>What is...
What does LA have to Offer?<br />Drug Information Association<br />www.diahome.org<br />7<br />Latin America provides:<br ...
a diverse population of over 560 million inhabitants with massive patient populations in all therapeutic indications
a ready and professional supply of research facilities and
contract research organizations offering professional services for partnering solutions in clinical trial conduction.</li>...
Therapeutic Indications<br />Drug Information Association<br />www.diahome.org<br />9<br /><ul><li>Oncology
Cardiovascular
Gastroenterology
Neurology
Orthopedic/DVT
Hematology
Upcoming SlideShare
Loading in...5
×

Dia feb 2010 final presentation webinar 2 mll

1,462

Published on

Published in: Education
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,462
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
43
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Dia feb 2010 final presentation webinar 2 mll

  1. 1. Expanding Clinical Research Beyond Borders:<br /> The Importance of Latin America<br /> Dr. Marlene Llopiz<br />Venn Life Sciences<br /> Mexico<br />
  2. 2. Growing markets<br />Introduce Latin America (LATAM)<br />Describe what Latin America has to offer<br />What is available in LATAM?<br />What about quality?<br />What about timelines?<br />Assess the possibility of conducting global trials in LA <br />Analyze the overall challenges for Latin American countries<br />Aims and Objectives<br />2<br />www.diahome.org<br />Drug Information Association<br />
  3. 3. Latin America (LA)<br />Drug Information Association<br />www.diahome.org<br />3<br />Regions:<br /><ul><li>Mexico
  4. 4. Central America
  5. 5. Caribbean
  6. 6. South America</li></ul>Clinicalresearchin:<br /><ul><li>Mexico
  7. 7. Argentina
  8. 8. Guatemala
  9. 9. Costa Rica
  10. 10. Panama
  11. 11. Colombia
  12. 12. Venezuela
  13. 13. Peru
  14. 14. Chile
  15. 15. Brazil</li></li></ul><li>Growing Markets Playing an Increasingly Important Role<br />Drug Information Association<br />www.diahome.org<br />4<br />Average Relative Annual Growth Rate of Clinical Trials in Major Regions<br />Growth Rate<br />Source: Thiers et al., Nature Reviews Drug Discovery, January 2008<br />
  16. 16. In recent years, several regions around the world have provided new frontiers for conducting phase I-IV clinical trials. <br /> Latin America has come into the limelight for pharmaceutical studies.<br />Introduction: The Importance of LA<br />5<br />
  17. 17. As a vastly populated and varied region, LA provides:<br /><ul><li>large drug naïve patient populations with common and special disease profiles,
  18. 18. rapid compliant patient recruitment,
  19. 19. motivated and experienced investigators,
  20. 20. USA and EC-equivalent medical standards, as well as
  21. 21. highly experienced monitoring and project management teams thoroughly trained on GCP and ICH guidelines. </li></ul>What is available in LA?<br />6<br />
  22. 22. What does LA have to Offer?<br />Drug Information Association<br />www.diahome.org<br />7<br />Latin America provides:<br /><ul><li>an excellent geographical location
  23. 23. a diverse population of over 560 million inhabitants with massive patient populations in all therapeutic indications
  24. 24. a ready and professional supply of research facilities and
  25. 25. contract research organizations offering professional services for partnering solutions in clinical trial conduction.</li></li></ul><li>What about quality?<br />Drug Information Association<br />www.diahome.org<br />8<br />Healthcare systems in LA have changed substantially throughout the last years. <br />Research has become more proficient with improved standards of operation. <br />Regulations have become stricter and formal in line with foreign regulatory and health authorities. <br />
  26. 26. Therapeutic Indications<br />Drug Information Association<br />www.diahome.org<br />9<br /><ul><li>Oncology
  27. 27. Cardiovascular
  28. 28. Gastroenterology
  29. 29. Neurology
  30. 30. Orthopedic/DVT
  31. 31. Hematology
  32. 32. HIV/AIDS
  33. 33. Osteoporosis
  34. 34. Immunology
  35. 35. Endocrine/Metabolic
  36. 36. Respiratory
  37. 37. Urology
  38. 38. Dermatology
  39. 39. Psychiatry
  40. 40. Paediatric experience
  41. 41. Women’s Health
  42. 42. Devices</li></li></ul><li>Disease Demographics – Latin America<br />Leading causes of death:<br />Heart disease<br />Cancer<br />Infectious diseases<br />Diabetes<br />Mortality rates from infectious diseases are declining<br />Incidence of cancer and chronic and lifestyle diseases, heart disease, stroke and diabetes rising; type 2 diabetes increasing dramatically<br />Prevalence of diabetes in Mexico is among the world’s highest at 10.6% of adults<br />International Diabetes Federation estimates there are 6.9 million people in Brazil and 6.1 million people in Mexico with diabetes<br />Drug Information Association<br />www.diahome.org<br />10<br />
  43. 43. Careful selection is made of each Latin American country to participate in global trials dependent on the shortness and complexity or lack thereof of complications for study conduction and of course, patients, sites and investigator availability.<br />Country Selection<br />Drug Information Association<br />www.diahome.org<br />11<br />
  44. 44. Principal investigators and sites are adequately selected meeting and complying with protocol and study needs and requirements with the necessary experience.<br />Site and PI Selection<br />Drug Information Association<br />www.diahome.org<br />12<br />
  45. 45. Non-disclosure agreements signed<br />Reception of protocols (or synopsis) and request for proposal from clients (at a local or corporate level) are received<br />Protocols (or protocol synopsis) are reviewed<br />Therapeutic indication is carefully analyzed (incidence and prevalence of the disease in each country)<br />Proposals with budgets are submitted dependent on country, sites, patients, complexity of trial, etc.<br />Steps to be Taken for Clinical Trials in LA<br />Drug Information Association<br />www.diahome.org<br />13<br />
  46. 46. Confidentiality agreements are signed with investigators and site facilities that are pre-selected dependent on client indication<br />Feasibility studies are conducted or recommended sites and investigators reviewed (based on protocol purpose, therapeutic indication, patient recruitment, etc.)<br />Once sites are selected, all documents are translated into Spanish (and Portuguese for Brazil).<br />Powers of Attorney must be obtained for the CRO to manage the trial.<br />Steps to be Taken for Clinical Trials in LA<br />Drug Information Association<br />www.diahome.org<br />14<br />
  47. 47. A description letter of the study is submitted to the Ethics Committee (EC) together with: <br />the protocol, <br />informed consent form, <br />investigator´s brochure, <br />patient diaries and <br />CRF´s <br />(Documents submitted in the language of submission (Spanish) in addition to English)<br />Each site will have a fee that must be paid.<br />Steps to be Taken<br />Drug Information Association<br />www.diahome.org<br />15<br />
  48. 48. Once approval from EC is obtained and a letter of authorization is obtained, Ministry of Health (MoH) submission must be officially made submitting all study and site documents in English and Spanish. <br />In certain countries, after approval from a local EC is obtained, then documents must be submitted to a national EC<br />Once MoH approval is obtained, an import license must be solicited providing the manufacturer´s and supplier´s name and address and a description of the product and quantity.<br />At each institution, a fee will have to be paid for each procedure.<br />Steps to be Taken<br />Drug Information Association<br />www.diahome.org<br />16<br />
  49. 49. Certified warehouses are contracted for study supply receipt and distribution to sites. <br />In sum, regulatory submission and approvals vary per country.<br />Regulatory Timelines<br />Drug Information Association<br />www.diahome.org<br />17<br />
  50. 50. Drug Information Association<br />www.diahome.org<br />18<br />Regulatory TimelinesLATAM Country Comparison<br />Drug Information Association<br />www.diahome.org<br />18<br />
  51. 51. Recommended Label Requirements<br />In Spanish<br />Protocol reference number/title<br />Contents<br />Administration route<br />Lot/reference number<br />Expiration date<br />Storage conditions<br />For Investigational Use Only<br />Keep out of reach of children<br />Manufacturer or Sponsor´s name and address.<br />Drug Information Association<br />www.diahome.org<br />19<br />
  52. 52. Import License – after protocol approval<br /> Timeline: 2-3 weeks<br />Rule 4.3: to import samples from an approved protocol (non-controlled drugs and lab kits).<br />Exportation: rule 4.3 also allows to export human tissue or serum samples.<br />Import/Export Process<br />Drug Information Association<br />www.diahome.org<br />20<br />
  53. 53. Serious Adverse Reactions (SARs): 7 days after site´s notification plus 8 days to complete the information.<br />Non-serious adverse reactions to be reported at the end of the study.<br />Safety letters should be sent every 6 months for phase IV studies. <br />For Phase I-III trials, the reports are sent at the end of the study.<br />Pharmacovigilance Standard (NOM-220-SSA1-2002)<br />Official Communications from CNFV<br />Safety Report<br />Drug Information Association<br />www.diahome.org<br />21<br />
  54. 54. Clinical Trial Approval in Mexico<br />Drug Information Association<br />www.diahome.org<br />22<br />Clinical Trial Approval in Mexico<br />Final Protocol (Spanish)<br />Investigator’s Drug Brochure (Spanish)<br />Informed Consent Form (Spanish)<br />Power of Attorney<br />Details on importation of CTM, labs<br />4-8 weeks<br />IRB/EC<br />SSA / Secretaria de Salud<br />(MOH)<br />4 – 6<br />weeks<br />Clinical Trial Approval Letter<br />2 – 3<br />weeks<br />Import License<br />Study Start<br />
  55. 55. Challenges with Clinical Research in Latin America<br />Drug Information Association<br />www.diahome.org<br />23<br /><ul><li>Regulatory environment continues to evolve; within the past few years, clinical trials in Brazil and Argentina have experienced long review times.
  56. 56. Import/export challenges
  57. 57. Competition for investigators and patients as more CROs and pharmaceutical companies conduct trials in the region
  58. 58. As in other emerging markets, EDC can be challenging – must ensure that the infrastructure and systems are in place</li></li></ul><li>Advantages of Conducting Trials in Latin America<br />Drug Information Association<br />www.diahome.org<br />24<br />Large, urban patient population enables faster enrollment and easier patient follow-up<br />Population sees clinical trials as a viable healthcare option to gain access to free medication. High patient retention rates.<br />More patients per site can be enrolled as compared with North America and Europe<br />Well-trained investigators knowledgeable in GCP and ICH guidelines<br />High level of investigator involvement in site activities<br />
  59. 59. Disease patterns that reflect both the West and the developing world<br />Opportunities for time efficiencies with seasonal disease trials<br />Region primarily uses just two languages: Portuguese (Brazil) and Spanish<br />Quality of data comparable to that of data collected in North America<br />Growing pharmaceutical market<br />Advantages of Conducting Trials in Latin America<br />Drug Information Association<br />www.diahome.org<br />25<br />
  60. 60. One of their main concerns is the timely fashion and quality of regulatory strategies to follow and comply with related to their studies to bring new drugs to market in these parts of the world.<br />Timelines<br />Drug Information Association<br />www.diahome.org<br />26<br />
  61. 61. Timely submissions and project start-ups are often difficult tasks due to the complexity of the necessary documentation required and delays in their delivery in each Latin American country versus differences with other continents.<br />Timelines<br />Drug Information Association<br />www.diahome.org<br />27<br />
  62. 62. Placing studies in Latin America provides:<br /><ul><li>pharmaceutical companies and contract research organizations an array of countries for testing drugs,
  63. 63. a reduction in costs with strategic multi-centered studies, and
  64. 64. credible and objective results for submission to higher regulatory authorities for marketing approvals.
  65. 65. International trial results could have significant medical importance and may have an impact on future products. </li></ul>Advantages to Studies in LATAM<br />Drug Information Association<br />www.diahome.org<br />28<br />
  66. 66. The fact that a given study is approved by FDA / EMEA does not necessarily mean that it will be approved by local MoHs throughout Latin America.<br />Avoid as much as possible the need to clarify or submit extra documents to the Ethics Committees and/or MoH after submitting the protocol for review. This significantly delays protocol approval.<br />Submit all documents together. Do not submit in bits and pieces.<br />Submit the protocol with as many amendments as possible.<br />Final Considerations<br />Drug Information Association<br />www.diahome.org<br />29<br />
  67. 67. Dr. Marlene Llópiz<br />Regional Director for Latin America<br />Venn Life Sciences Clinical Research<br />+52 55 9171- 0288<br />+52 1 55 3335 - 2952<br />(Mexico City)<br />marlene.llopiz@vlsworldwide.com<br />marlene.llopiz@post.harvard.edu<br />Contact Information<br />Drug Information Association<br />www.diahome.org<br />30<br />
  68. 68. Questions?<br />Clinical Trials and Regulatory Affairs in LA<br />Drug Information Association<br />www.diahome.org<br />31<br />
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×